


Figure 1




Figure 2




Figure 3

Bis-sulfone reagent 1 conjugate **Maleimide conjugate**




Figure 4



80
70
60
50
40
30
20
10
0
%Area at 280 nm
DAR 0
DAR 1
DAR 2
DAR 3
DAR 4
DAR >4

Figure 5



SK-BR-3
% viability
100
50
0
-3
-2
-1
0
1
Concentration (nM) log
MMAE
Antibody reagent 1 conjugate
BT-474
% viability
100
50
0
-3
-2
-1
0
1
Concentration (nM) log
MMAE
Antibody reagent 1 conjugate

Figure 6



BT-474
% viability
120
100
80
60
40
20
0
-2
-1
0
1
Log [Compound] (nM)
Reagent 6 conjugate
Reagent 9 conjugate
MMAE
SK-BR-3
% viability
120
100
80
60
40
20
0
-3
-2
-1
0
1
Log [Compound] (nM)
Reagent 6 conjugate
Reagent 9 conjugate
MMAE

Figure 7



1400
1200
1000
800
600
400
200
0
1
8
15
22
29
36
43
50
57
64
Vehicle
DAR 1
DAR 2
DAR 3
DAR 4

Figure 8



M
1
2
260 kDa
160 kDa
110 kDa
80 kDa
60 kDa
50 kDa
40 kDa
30 kDa
20 kDa
15 kDa
10 kDa
3.5 kDa
80 %
17 %
M
3
4
260 kDa
160 kDa
110 kDa
80 kDa
60 kDa
50 kDa
40 kDa
30 kDa
20 kDa
15 kDa
10 kDa
3.5 kDa
67 %
31 %
2H + 2L
H + L

Figure 9